gnc-038
biokin pharma
['nhl', 'gnc-038', 'leusm']
congress | #asco2023 | poster
jianxiang wang described the phase i rationale and clinical study design of gnc-038 for pts with r/r nhl or all consisting of a dose-escalation (ia) and dose-expansion (ib) phase. the dose expansion phase is underway
#allsm #leusm #medicalcongress 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm